CHARLOTTESVILLE, Va. (WDBJ) - A recent study by the University of Virginia School of Medicine is finding a new approach to boosting vaccination rates for older adults.

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

For example, with atirmociclib, our next generation highly selective CDK4 inhibitor candidate, yesterday, we dosed our first patient in a ... in the total adult RSV market volume, driven by ...

The reason I'm going to quote you directly from Slack here, David, the most uncertain revenue guidance I've ever seen. You care to elaborate on that? David Meier: Yes. I've been doing this a long time ...

Influenza A virus particles strategically adapt their shape—to become either spheres or larger filaments—to favor their ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

“Particularly in the last week or two we’ve started to see a significant uptick in the number of kids coming in with symptoms of RSV and flu, things like fever, runny nose, cough, trouble breathing,” ...

the condition is already noted as a potential complication in patient information, however not all of those who receive the jab will be warned verbally of the risks. Respiratory syncytial virus ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing ...